1. Home
  2. PETS vs SCYX Comparison

PETS vs SCYX Comparison

Compare PETS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PetMed Express Inc.

PETS

PetMed Express Inc.

HOLD

Current Price

$1.53

Market Cap

41.7M

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.39

Market Cap

44.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PETS
SCYX
Founded
1996
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.7M
44.4M
IPO Year
2003
2014

Fundamental Metrics

Financial Performance
Metric
PETS
SCYX
Price
$1.53
$4.39
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
★ $3.00
AVG Volume (30 Days)
★ 101.9K
56.1K
Earning Date
06-09-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 61.36
EPS
★ N/A
N/A
Revenue
★ $273,800,000.00
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.98
$608.78
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.55
$0.57
52 Week High
$4.10
$6.09

Technical Indicators

Market Signals
Indicator
PETS
SCYX
Relative Strength Index (RSI) 26.26 43.02
Support Level N/A $4.08
Resistance Level $1.91 $5.56
Average True Range (ATR) 0.05 0.37
MACD -0.01 -0.04
Stochastic Oscillator 0.00 26.77

Price Performance

Historical Comparison
PETS
SCYX

About PETS PetMed Express Inc.

PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: